Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MZE001 · 1 trial · 1 indication
Occurrence of adverse events, serious adverse events, adverse events of special interest
| Arm | Type | Description |
|---|---|---|
| MZE001 | EXPERIMENTAL | MZE001 is a small molecule inhibitor of muscle glycogen synthase for the potential treatment of Pompe disease. |
| Placebo | PLACEBO_COMPARATOR | Excipients containing no active ingredients. |
| Name | Type | Description |
|---|---|---|
| MZE001 | DRUG | Small molecule inhibitor of muscle glycogen synthase |
| Placebo | DRUG | Product containing excipients with no active ingredients |
Inclusion Criteria: 1. Male and female subjects, ages 18 - 55 years, inclusive; 2. Must provide written informed consent prior to any study assessments and be willing and able to comply with all study procedures; 3. Body mass index (BMI) between 18.0 and 32.0 kg/m2 inclusive; 4. Healthy as determin...
MZE001 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development and has not been approved for any condition. The drug is being evaluated for safety and tolerability in a clinical trial setting.
MZE001 is being developed by Maze Therapeutics, Inc., a biopharmaceutical company. The company is conducting clinical research on this investigational small molecule in the United States.
MZE001 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains in early-stage clinical research.
MZE001 was studied in a randomized, double-blind, placebo-controlled Phase 1 trial (NCT05249621) in healthy volunteers. The trial enrolled 121 participants aged 18 years and older in the United States and has been completed.
MZE001 is not FDA approved. It is an investigational small molecule currently in Phase 1 clinical development. The completed Phase 1 trial was designed to evaluate the drug in healthy volunteers, and it has not progressed to later-stage trials or regulatory approval.